FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine, particularly, to a conjugate of an insulinotropic peptide of prolonged action in vivo and stability, and containing an insulinotropic peptide selected from a group consisting from exendin-3 and exendin-4 and their derivatives, a nonpeptide polymer where one of the ends of a molecule of the nonpeptide polymer is connected with an amino acid residue different from a N-terminal residue of the insulinotropic peptide.
EFFECT: invention provides preparation of the conjugate of the insulinotropic peptide exhibiting activity in vivo which remains at a relatively high level, and substantially increased blood half-life, availability for development of the long-acting formulations based on various peptide drugs.
29 cl, 1 tbl, 18 dwg, 15 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF CONTROLLING CONDITIONS FOR SITE-SPECIFIC BINDING OF POLYPEPTIDE AND NON-PEPTIDE POLYMER | 2010 |
|
RU2495881C2 |
| COMPOSITION FOR TREATING DIABETES, CONTAINING LONG-ACTING INSULIN CONJUGATE AND LONG-ACTING INSULINOTROPIC PEPTIDE CONJUGATE | 2012 |
|
RU2606840C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATING OBESITY-RELATED DISEASES CONTAINING INSULINOTROPIC PEPTIDE CONJUGATE | 2008 |
|
RU2446816C2 |
| PHARMACEUTICAL COMPOSITION FOR NON-ALCOHOLIC FATTY LIVER DISEASE PREVENTION OR TREATMENT | 2013 |
|
RU2635966C2 |
| LIQUID COMPOSITION OF LONG-ACTING INSULIN AND INSULINOTROPIC PEPTIDE | 2013 |
|
RU2643766C2 |
| DERIVATIVE OF INSULINOTROPIC PEPTIDE THAT CONTAINS MODIFIED N-ENDED AMINOACID | 2008 |
|
RU2442792C2 |
| CONJUGATE CONTAINING OXINTOMODULIN AND IMMUNOGLOBULIN FRAGMENT, AND ITS APPLICATION | 2012 |
|
RU2733544C2 |
| CONJUGATE, CONTAINING OXYNTOMODULIN AND FRAGMENT OF IMMUNOGLOBULIN, AND USE THEREOF | 2012 |
|
RU2607365C2 |
| COMPOSITION FOR TREATING HYPERLIPIDEMIA CONTAINING AN OXYNTOMODULIN DERIVATIVE | 2013 |
|
RU2768853C1 |
| PHARMACEUTICAL COMPOSITION CONTAINING Fc-REGION OF IMMUNOGLOBULIN AS CARRIER | 2004 |
|
RU2352583C2 |
